Mr Cooper Group Inc (COOP): They are holding up very well considerin...

They are holding up very well considering.

DarkB4Dawn · 2025-04-03T16:32:55.9700000Z

They are holding up very well considering. Here is the presentation and pro forma for both acquisitions as "pitched" for the call past Monday. https://s205.q4cdn.com/636124780/files/presentation/2025/04/Rocket-Companies-Mr-Cooper-Transaction-Presentation_vf.pdf

Play Episode

6min

Proactive - Interviews for investors

Zynex Medical champions noninvasive, non-addictive pain management with NexWave

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

European defense spending boom: Key investment opportunities amid global shifts

Jane Edmondson, Head of Index Product Strategy at TMXVettaFi, joined Steve Darling from Proactive to discuss the rapidly evolving global defense landscape and its investment implications. With geopolitical tensions on the rise and shifting defense priorities, investors must navigate new opportunities and risks in the sector. Edmondson highlighted Europe's unprecedented surge in defense spending, a direct response to the U.S. decision to scale back military aid to Ukraine. Central to this shift is the European Union’s €800 billion "Rearm Europe Readiness 2030" initiative, aimed at bolstering military preparedness. This includes substantial investments across key defense technologies and a dedicated €150 billion credit facility to enhance military capabilities. “There’s going to be a lot of spending to come,” Edmondson noted, emphasizing major growth areas such as artificial intelligence, cyber defense, drone technology, and advanced artillery systems. She pointed out that leading European defense firms—including Rheinmetall, BAE Systems, Thales, Dassault, and Leonardo SPA—stand to benefit significantly from this expansion. Additionally, South Korea’s Hanwha Aerospace is emerging as a key player in global defense contracts. In contrast, U.S. defense companies are experiencing headwinds due to budget cuts and canceled procurement deals, leading to a relative downturn in the sector. Another critical shift in global defense procurement is unfolding as traditional U.S. allies reconsider their defense purchases. Canada and Portugal, for instance, are re-evaluating orders for U.S.-made F-35 fighter jets in favor of alternative options, such as aircraft from Dassault Aviation. Edmondson stressed that these geopolitical realignments are creating strong economic tailwinds, particularly for Germany, which is set to invest an estimated €500 billion in defense over the next several years. She cited a recent Goldman Sachs report, which projects that half of this spending will

Proactive - Interviews for investors

ACG Metals CFO says hold hedge strategy is already paying off

ACG Metals Ltd chief financial officer Patrick Henze talked with Proactive's Stephen Gunnion about the company’s recently announced gold hedging strategy and its importance during ACG’s transition phase from precious to base metals. Henze explained that while ACG Metals is ultimately targeting copper production from its Gediktepe mine in Turkey by 2026, the mine currently generates strong cash flow from gold and silver. The company has moved to hedge 50% of its gold production at US$2,875 per ounce through January 2026, helping secure revenue in a volatile pricing environment. He noted: “We are currently producing gold and silver, which is a perfect transition for us to become a copper producer in ’26… we can benefit and protect a bit the cash flows by hedging the gold.” The hedge program, executed with Alpha, involves no cash outlay and allows ACG to retain upside exposure above US$3,065 per ounce on the hedged portion. Henze emphasised this strategy helps ACG provide more certainty to bondholders and equity investors by de-risking key financial metrics for 2025. The company remains unhedged on silver and copper, maintaining exposure for future upside. For more updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #ACGMetals #GoldHedging #CopperTransition #GediktepeMine #MiningStrategy #GoldPrices #Commodities #CashFlowManagement #MiningInvestment #ProactiveInvestors

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Followers	15
Posts	520
Boards Moderated	0
Alias Born	12/04/2016

Volume:	2,332,242
Day Range:	125.605 - 136.79
Bid:	118.93
Ask:	131.00
Last Trade Time:	7:17:07 PM EDT
Total Trades:	41,059

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

COOP Detailed Quote

Recent COOP News

More COOP News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent COOP News

Go Ad-Free